1. Academic Validation
  2. Identification of ZDHHC17 as a Potential Drug Target for Swine Acute Diarrhea Syndrome Coronavirus Infection

Identification of ZDHHC17 as a Potential Drug Target for Swine Acute Diarrhea Syndrome Coronavirus Infection

  • mBio. 2021 Oct 26;12(5):e0234221. doi: 10.1128/mBio.02342-21.
Yun Luo  # 1 2 Chee Wah Tan  # 3 Shi-Zhe Xie  # 1 2 Ying Chen 1 2 Yu-Lin Yao 1 Kai Zhao 1 Yan Zhu 1 Qi Wang 1 2 Mei-Qin Liu 1 2 Xing-Lou Yang 1 Lin-Fa Wang 3 Zheng-Li Shi 1
Affiliations

Affiliations

  • 1 CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virologygrid.439104.b, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
  • 2 University of Chinese Academy of Sciences, Beijing, China.
  • 3 Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
  • # Contributed equally.
Abstract

The recent emergence and spread of zoonotic viruses highlights that animal-sourced viruses are the biggest threat to global public health. Swine acute diarrhea syndrome coronavirus (SADS-CoV) is an HKU2-related bat coronavirus that was spilled over from Rhinolophus bats to swine, causing large-scale outbreaks of severe diarrhea disease in piglets in China. Unlike other porcine coronaviruses, SADS-CoV possesses broad species tissue tropism, including primary human cells, implying a significant risk of cross-species spillover. To explore host dependency factors for SADS-CoV as therapeutic targets, we employed genome-wide CRISPR knockout library screening in HeLa cells. Consistent with two independent screens, we identified the zinc finger DHHC-type palmitoyltransferase 17 (ZDHHC17 or ZD17) as an important host factor for SADS-CoV Infection. Through truncation mutagenesis, we demonstrated that the DHHC domain of ZD17 that is involved in palmitoylation is important for SADS-CoV Infection. Mechanistic studies revealed that ZD17 is required for SADS-CoV genomic RNA replication. Treatment of infected cells with the palmitoylation inhibitor 2-bromopalmitate (2-BP) significantly suppressed SADS-CoV Infection. Our findings provide insight on SADS-CoV-host interactions and a potential therapeutic application. IMPORTANCE The recent emergence of deadly zoonotic viral diseases, including Ebola virus and SARS-CoV-2, emphasizes the importance of pandemic preparedness for the animal-sourced viruses with potential risk of animal-to-human spillover. Over the last 2 decades, three significant coronaviruses of bat origin, SARS-CoV, MERS-CoV, and SARS-CoV-2, have caused millions of deaths with significant economy and public health impacts. Lack of effective therapeutics against these coronaviruses was one of the contributing factors to such losses. Although SADS-CoV, another coronavirus of bat origin, was only known to cause fatal diarrhea disease in piglets, the ability to infect cells derived from multiple species, including human, highlights the potential risk of animal-to-human spillover. As part of our effort in pandemic preparedness, we explore SADS-CoV host dependency factors as targets for host-directed therapeutic development and found zinc finger DHHC-type palmitoyltransferase 17 is a promising drug target against SADS-CoV replication. We also demonstrated that a palmitoylation inhibitor, 2-bromopalmitate (2-BP), can be used as an inhibitor for SADS-CoV treatment.

Keywords

2-bromopalmitate; CRISPR-Cas9 screen; DHHC domain; SADS-CoV.

Figures
Products